MedPath

Camrelizumab

Generic Name
Camrelizumab
Drug Type
Biotech
CAS Number
1798286-48-2
Unique Ingredient Identifier
73096E137E

Overview

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Indication

⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。 ⑵用于霍奇金淋巴瘤(三线)、肝细胞癌(二线)、非鳞状非小细胞肺癌(一线联合)、食管鳞癌(二线)。 ⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。 ⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/07/09
Not Applicable
Recruiting
Hebei Medical University Fourth Hospital
2025/07/08
Not Applicable
Completed
2025/02/27
Phase 2
Not yet recruiting
2025/02/17
Phase 2
Recruiting
2025/01/06
Phase 2
Not yet recruiting
Zhejiang University
2024/12/12
Phase 2
Not yet recruiting
2024/11/19
Phase 2
Not yet recruiting
2024/11/18
Phase 2
Not yet recruiting
Peking University Shenzhen Hospital
2024/11/18
Phase 2
Not yet recruiting
2024/11/01
Phase 3
Recruiting
Sun Yat-sen University

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Camrelizumab for Injection
国药准字S20190027
生物制品
注射剂
5/29/2019

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath